reason report
fli combo fli strong tripl data offer upsid pt
bottom line vertex report result market close
yesterday also disclos top-lin result second pair tripl
combin phase ii trial announc first candid
phase tripl combin develop expect
suggest pre-quart preview compani comfort beat
consensu expect anticip provid top-
line guidanc compani await approv new
tez-iva doublet combin compani provid top-lin result
two second wave tripl combin
combin achiev remark improv
four week dose combin tezacaftor ivacaftor
challeng het-min cystic fibrosi cf patient deliv
impress reduct sweat chlorid highest dose
test qd produc reduct
highest dose slightli advers event
discontinu margin look
cleaner effect two molecul although
patient number still small patient per trial compani
appear focus prefer second gener
corrector combin partner develop although
also advanc pivot trial first tripl combin
pivot trial tez/iva begin pend final studi
design fda initi focu het min patient although
pivot trial homozyg patient like
month behind vertex expect start second pivot trial program
mid year like incorpor deuter
ivacaftor licens concert consist medicin dose
daili basi
result perform increment disclosur
updat model includ increas sale expect
tez/iva tripl combin launch year weve
increas forecast oper expens due compani
guidanc increas effect tax rate forecast
updat price target previous
reiter outperform rate vertex stock
average ep rev
disc dcf wacc
tg
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu million
pleas refer page import disclosur price chart analyst certif
price target vertex rate stock outperform thesi base
expect continu captur cystic fibrosi cf patient subpopul vertex
success iter cf modul oral combin medicin expect
vertex cf revenu line grow steadili
probabl success tripl combin valuat account
full expect valu cf portfolio consid competitor forecast
valuat believ develop path time market challeng vertex
well posit partner acquir show promis flirt profit
past vertex seem determin maintain recent recov profit appear
capabl grow oper margin end
beyond compani still aspir discov develop drug categori larg
diversifi invest associ expens risk thesi valuat howev
potenti sizabl near-term growth stock offer strong valuat upsid potenti
next month
revenu grew qoq yoy beat consensu estim
vertex report revenu beat consensu estim
orkambi sale fell short above-consensu estim beat
consensu kalydeco revenu beat estim consensu
compani disclos channel inventori build us pre-ord
certain market outsid us quarter boost sale non-recur
even net item revenu would consensu vertex gross margin
line expect discretionari expens sg
approxim line estim consensu usual
compani modest tax oblig non ep
estim beat consensu wide margin speak manag
follow earn call confirm us key driver result strong
growth kalydeco us market base recent label expans growth
orkambi mostli intern market
impress phase ii result best profil
vertex report result long-await phase ii trial tripl combin remain
two next-gener corrector result turn
encourag report last juli strong data support
compani decis pick upcom phase develop
program like phase dose improv
percentag point placebo-adjust respect reduct sweat chlorid
placebo-adjust respect compar best result
compani earlier combin last juli improv sweat chlorid
reduct result repres higher delta needless say
scale effect sever time higher orkambi achiev popul
low frequenc sever advers event discontinu safeti profil
appear attract compar two particularli better
confirm phase trial data set high bar develop entri
potenti competitor drive faster reimburs deeper adopt compar
adopt fund earlier combin orkambi
phase consist tripl combin
first vertex phase tripl combin trial begin year tripl
combin follow second group phase tripl trial earli
initi studi difficult het-min popul
vertex plan start two addit studi combin earli
much larger homozyg popul well initi data suggest
might best next-gen corrector vertex thought sensibl mitig risk
includ differ corrector along deuter ivacaftor combin
manag team suggest event becom compromis
unforeseen safeti issu would abl rapidli bridg bioequival
work alreadi prepar vertex still discuss fda regard trial
design specif durat efficaci safeti observ need regulatori file
view efficaci trial like would posit investor could
still result tripl combin potenti come market late slightli earlier
previous forecast
tez/iva around corner offer upsid
pdufa tezacaftor/ivacaftor remain near-term catalyst stock even
consensu incorpor high probabl event success launch
tez/iva monitor close orkambi-switch increment penetr
previous untreat popul individu discontinu orkambi
toler reason base notion view addit tez/iva vertex cf portfolio
drive signific addit valu see upsid term adopt revenu growth
addit combin
pipelin program becom visibl valuabl
quarterli updat vertex provid guidanc begin phase i/ii studi two
indic gene edit candid partner
incorpor crispr technolog initi studi pair phase i/ii
trial beta-thalassemia sickl cell diseas vertex also expect
report result phase ii studi acut pain select sodium channel blocker
also investig on-going studi treatment pain caus small
fiber neuropathi vertex yet provid detail regard design trial
current assign valuat either program
model
leerink revenu ep estim updat
follow quarterli updat increment disclosur compani made
adjust market compani revenu expens tax forecast come year
reflect updat view compani outlook total cf product revenu forecast
increas futur year mostli due increas sale
expect tez/iva tripl combin regimen initi launch year
updat total revenu forecast recent consensu
consensu subsequ year increas total oper expens forecast
year base compani recent disclosur launch tez/iva
tripl combin well includ increas expens final wave cf
develop account earlier stage program move clinic
increas effect tax rate five percentag point rate
pro forma dilut ep increas
pro forma dilut ep estim
recent consensu result chang price target increas
previous reiter outperform rate vertex stock
price target vertex base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl high growth larg cap biopharmaceut compani price sale multipl
mid larg cap high growth biopharmaceut compani discount cash flow dcf
use current averag high growth larg cap biopharma multipl ep
nvo appli current ep estim discount
back year compani cost equiti give valu one year use
averag high growth larg cap biotech price-to-revenu multipl sale
nvo appli revenu estim post-tripl
discount back year compani cost equiti give valu one year
lastli dcf valuat given wacc termin cash flow growth rate give
present valu averag three method current price target
risk view outlook valuat vertex includ major chang price
reimburs coverag label competit posit kalydeco orkambi
compani main product today major risk disappoint delay failur
compani develop regulatori file second first gener cf corrector
tezacaftor compani much-anticip dual corrector/potenti tripl combin
program risk includ acceler success develop altern modul
cftr altern approach treat cf gene therapi final compani
histori spend much potenti earn expens diversifi acquisit could
undermin futur expect valu compani cf portfolio opportun better-than
expect perform includ realiz signific revenu compani current cf
dual combin market outsid us well acceler clinic develop
sale non-gaap
non-gaap interest expens net
share count period basic
share count period dilut
guidanc
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time result
earlier
het min cf cf
het min cf cf
regulatori file
us/eu yr old
start phase tripl
start phase tripl
start phase tripl
start phase tripl
eu approv
million
product sale po adjust
tripl combin kalydeco second corrector full year sale
total product sale book
product sale po adjust
total product sale book
leerink partner research compani file
million
product sale direct product sale vertex
sale
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink target
method large-cap healthcar ep multipl lp normal earn
current averag high growth larg cap high growth biopharma multipl ep
leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
present valu late stage market product flow
net debt end
averag method
leerink partner research compani file factset
